Access Program Information
This is an expanded access protocol to allow continued maintenance therapy with ABT-888
(veliparib) for three patients with metastatic triple negative breast cancer who are
currently receiving the investigational product in association with clinical trial
participation. Additionally, the protocol will enroll up to 7 new patients with metastatic
BRCA associated or triple negative breast cancer to allow for additional access to veliparib
monotherapy, or at the investigator’s discretion, veliparib in combination with cisplatin
and/or vinorelbine.